by Raynovich Rod | Jul 29, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big...
by Raynovich Rod | Jul 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jul 15, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with...
by Raynovich Rod | Jul 14, 2014 | Biopharmaceuticals
Healthcare Stocks trail other sectors up 0.34%, Energy up 0.8%, Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up...
by Raynovich Rod | Jul 8, 2014 | Biopharmaceuticals
Re-iterate call from Tuesday….futures down 0.8%-Russell down 2%, gold up, Japan and Europe down.. Bad Tape Yesterday (7/7) Calls For Raising Cash NASDAQ at 4451 up 6.58% YTD Major ETFs and Fidelity (FBIOX) take a ~3% hit All major market sectors weak with...
by Raynovich Rod | Jul 3, 2014 | Biopharmaceuticals
Rayno Diagnostics and Tools-Sequencing Rules Diagnostics and Tools stocks tracked biotech stocks during the huge moves in January/February and sold off until the April bottom. However stocks that are more revenue and earnings driven -Cardiovascular Systems(CSII) and...
by Raynovich Rod | Jul 2, 2014 | Biopharmaceuticals
Biopharmaceutical Stocks Come Roaring Back After Q1 Correction Most Stocks Bottomed in April -We are Currently in Rally Mode The biotech sector is up 18% YTD as tracked by most popular ETFs (FBT,IBB,XBI). After a vicious sell-off from the February bubble the biotech...
by Raynovich Rod | Jul 1, 2014 | Biopharmaceuticals
2014 YTD- ETFs Outperformed Managed Funds In Biotech In the past managed life science funds outperformed ETFs but this has reversed in 2014. Fidelity’s flagship Select Biotechnology Portfolio (FBIOX) is up 10% YTD and 41.4% over one year, and 229.6% over 5...
by Raynovich Rod | Jun 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and...
by Raynovich Rod | Jun 26, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum...
